ORLEANS, ON, Feb. 20, 2020 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or
the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global
leader in cannabinoid-based drug development and discovery, is
pleased to announce that a total of 31,292,471 common share
purchase warrants (the "Warrants") of the Corporation will
be listed and posted for trading under the symbol TBP.WT.B on the
TSX Venture Exchange effective on or about February 25, 2020.
The Warrants were issued in connection with the Corporation's
bought deal prospectus offering of Units (the "Units") that
closed on February 13, 2020 (the
"Offering"). Each Unit consisted of one common share
(a "Common Share") and one Warrant. Each Warrant
entitles the holder thereof to purchase one Common Share at an
exercise price equal to $0.75 at any
time before February 13, 2023. The
Warrants to be listed on the TSX Venture Exchange also include a
total of 2,047,171 Warrants which were issued to Echelon Wealth
Partners Inc. as compensation for their services as underwriter for
the Offering, as described in the Corporation's final short form
prospectus dated February 6,
2020.
The Warrants are governed by the terms of a Warrant Indenture
dated February 13, 2020 between the
Corporation and Computershare Trust Company of Canada as warrant agent, a copy of which is
available under the Corporation's profile at www.sedar.com. For
further details regarding the Warrants, please refer to the Warrant
Indenture.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a
biopharmaceutical leader in cannabinoid-based drug discovery and
development with a Health Canada approved, and FDA reviewed,
clinical program aimed at bringing novel prescription drugs and
treatments to patients and their healthcare providers. The Company
has several subsidiaries engaged in the development of an advanced
and growing pipeline of Bio Pharmaceuticals, Natural Health and
Veterinary Products containing cannabis and other medicinal
plant-based elements. With patients at the core of what we do,
Tetra Bio-Pharma is focused on providing rigorous 2 scientific
validation and safety data required for inclusion into the existing
bio pharma industry by regulators, physicians and insurance
companies.
Some statements in this release may contain forward-looking
information, including statements regarding the intended date when
the Warrants will commence trading. All statements, other than of
historical fact, that address activities, events or developments
that the Company believes, expects or anticipates will or may occur
in the future (including, without limitation, statements regarding
potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable
by use of the words "may", "will", "should", "continue", "expect",
"anticipate", "estimate", "believe", "intend", "plan" or "project"
or the negative of these words or other variations on these words
or comparable terminology. Forward-looking statements are subject
to a number of risks and uncertainties, many of which are beyond
the Company's ability to control or predict, that may cause the
actual results of the Company to differ materially from those
discussed in the forward-looking statements. Factors that could
cause actual results or events to differ materially from current
expectations include, among other things, without limitation, the
inability of the Company to obtain sufficient financing to execute
the Company's business plan; competition; regulation and
anticipated and unanticipated costs and delays, the success of the
Company's research and development strategies, including the
success of this product or any other product, the applicability of
the discoveries made therein, the successful and timely completion
and uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma Inc.